Literature DB >> 9517872

Frequency and determinants of use of antiretroviral and prophylactic therapies against Pneumocystis carinii Pneumonia (PCP) before AIDS diagnosis in Italy.

P A Napoli1, M Dorrucci, D Serraino, P Pezzotti, S Franceschi, S Vella, G Rezza.   

Abstract

To determine the frequency and the determinants of use of antiretroviral drugs and prophylaxis for Pneumocystis carinii Pneumonia (PCP) among HIV-infected individuals before AIDS diagnosis, a questionnaire was sent to all physicians reporting at least one AIDS case during the first six months of 1994 to the Italian National AIDS Registry. Information on cases diagnosed between 1 January and 31 March 1995 was collected. Information was obtained for 878 (66.4%) of the 1323 persons with AIDS: 447 (50.9%) had received antiretroviral drugs and 343 (39.1%) PCP prophylaxis, whereas 303 cases (34.5%) had received both. Individuals who became aware of being HIV-positive shortly before AIDS diagnosis were less likely to have started antiretroviral therapy (adjusted odds ratio (AOR): 0.05, 95% CI: 0.03-0.09). Homosexual men and heterosexuals were more likely to begin therapy (AOR: 1.40, 95% CI: 0.83-2.37 and AOR: 1.79, 95% CI: 1.05-3.05, respectively) compared to injecting drug users. Individuals living in Southern Italy and foreigners were less likely to start therapy (AOR: 0.75, 95% CI: 0.49-1.16 and AOR: 0.40, 95% CI: 0.15-1.09, respectively) compared to those living in Northern Italy. Results were similar for PCP prophylaxis. Lack of awareness of HIV infection, HIV exposure category, and geographical area were the most important factors associated with treatment before AIDS diagnosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9517872     DOI: 10.1023/a:1007400519792

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  32 in total

Review 1.  Will we ever know when to treat HIV infection?

Authors:  A N Phillips; G D Smith; M A Johnson
Journal:  BMJ       Date:  1996-09-07

2.  Impact of treatment and prophylaxis on presentation and survival of patients with AIDS in Milan.

Authors:  A Monforte; F Mainini; M Musicco; T Formenti; M Mena; T Bini; M Moroni
Journal:  Lancet       Date:  1995-12-02       Impact factor: 79.321

3.  A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.

Authors:  S M Hammer; D A Katzenstein; M D Hughes; H Gundacker; R T Schooley; R H Haubrich; W K Henry; M M Lederman; J P Phair; M Niu; M S Hirsch; T C Merigan
Journal:  N Engl J Med       Date:  1996-10-10       Impact factor: 91.245

Review 4.  Antiretroviral drugs for AIDS.

Authors:  J J Lipsky
Journal:  Lancet       Date:  1996-09-21       Impact factor: 79.321

5.  A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group.

Authors:  J O Kahn; S W Lagakos; D D Richman; A Cross; C Pettinelli; S H Liou; M Brown; P A Volberding; C S Crumpacker; G Beall
Journal:  N Engl J Med       Date:  1992-08-27       Impact factor: 91.245

6.  Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. AIDS in Europe Study Group.

Authors:  J D Lundgren; A N Phillips; C Pedersen; N Clumeck; J M Gatell; A M Johnson; B Ledergerber; S Vella; J O Nielsen
Journal:  JAMA       Date:  1994-04-13       Impact factor: 56.272

7.  The incidence and prevalence of AIDS and prevalence of other severe HIV disease in England and Wales for 1995 to 1999: projections using data to the end of 1994.

Authors: 
Journal:  Commun Dis Rep CDR Rev       Date:  1996-01-05

Review 8.  Recommendations for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus. U.S. Public Health Service Task Force on Antipneumocystis Prophylaxis in Patients with Human Immunodeficiency Virus Infection.

Authors: 
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1993-01

9.  The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.

Authors:  M A Fischl; D D Richman; N Hansen; A C Collier; J T Carey; M F Para; W D Hardy; R Dolin; W G Powderly; J D Allan
Journal:  Ann Intern Med       Date:  1990-05-15       Impact factor: 25.391

10.  Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.

Authors:  P A Volberding; S W Lagakos; M A Koch; C Pettinelli; M W Myers; D K Booth; H H Balfour; R C Reichman; J A Bartlett; M S Hirsch
Journal:  N Engl J Med       Date:  1990-04-05       Impact factor: 91.245

View more
  2 in total

1.  Sexual behaviour of heterosexual individuals with HIV infection naive for antiretroviral therapy in Italy.

Authors:  E Girardi; M S Aloisi; D Serraino; M Ferrara; F N Lauria; M Carballo; A d'Arminio Monforte; G Rezza; M Moroni; G Carosi; A Alessandrini; D Giacobbi; L Cremonini; S Ranieri; M Montroni; G Ippolito
Journal:  Sex Transm Infect       Date:  2001-04       Impact factor: 3.519

2.  Impact of chemorophylaxis policy for AIDS-immunocompromised patients on emergence of bacterial resistance.

Authors:  Ashley A DeNegre; Kellen Myers; Nina H Fefferman
Journal:  PLoS One       Date:  2020-01-30       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.